用Botox (onabotulinumtoxinA) 治疗超症:发展,见解和影响
Nicholas Lowe1, Markus Naumann2, Nina Eadie3
1Cranley Clinic, London, UK.
Medicine
|July 27, 2023
概括
有机毒素A显著减少慢性过度出汗 (过) 并改善生活质量. 这种新的治疗方法为超患者提供了快速,持久的缓解,具有耐受性良好的安全性.
科学领域:
- 皮肤病学 皮肤病学
- 神经学 神经学
- 临床药理学 临床药理学
背景情况:
- 过严重影响情绪和社会福祉.
- 之前用于过的局部疗法有效性有限,需要频繁的治疗.
- 胺毒素A作为一种新的治疗方法,通过皮内注射治疗汗腺.
研究的目的:
- 为了建立适当的剂量和管理培训,在超症中使用甲毒素A.
- 开发和验证超症疾病严重程度尺度 (HDSS) 以测量疾病影响.
- 评估与onabotulinumtoxinA治疗相关的安全性,疗效和生活质量改善.
主要方法:
- 进行了2个双盲,安慰剂控制的关键试验,用于在高症中治疗甲胺毒素A.
- 利用下汗液产生的重力度测量和HDSS进行疗效评估.
- 进行了免疫性研究,长期安全性和疗效评估以及生活质量评估.
主要成果:
- 与安慰剂相比,onabotulinumtoxinA显著降低了股汗液的产生.
- 在HDSS上减少2个或更多的点表明过严重程度的显著改善.
- 治疗效果是快速的 (在1周内),持续至少6个月,并显著改善了生活质量.
结论:
- 毒素A是一种有效且耐受性良好的过症治疗方法,可提供快速和持续的缓解.
- HDSS的开发为测量超的影响提供了至关重要的工具.
- 治疗导致患者满意度提高,减少日常生活的影响,增强情绪健康.
相关概念视频
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
705
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
705
Cholinergic Antagonists: Therapeutic Uses
776
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
776
Direct-Acting Cholinergic Agonists: Therapeutic Uses
791
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
791
Skeletal Muscle Relaxants: Therapeutic Uses
515
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
515
Myasthenia Gravis: Overview and Treatment
1.6K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.6K
Drugs Acting on Autonomic Ganglia: Blockers
1.1K
Ganglionic blockers inhibit autonomic activity by blocking nicotinic receptors in the autonomic ganglia, suppressing impulse transmission. These blockers lack selectivity between sympathetic and parasympathetic ganglia and are ineffective as neuromuscular junction antagonists. They can be categorized into two groups:
1.1K


